SCHEMBL21522397

SCHEMBL21522397

N#Cc1ccc(N2CCC3(CCNC3)C2)nc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RET P07949 9/20 0.52
CYP3A4 P08684 4/20 0.52
ALDH1A1 P00352 3/20 0.52
HSD17B10 Q99714 3/20 0.52
HPGD P15428 2/20 0.52
CYP1A2 P05177 2/20 0.44
CYP2D6 P10635 2/20 0.44
TSHR P16473 2/20 0.44
PTPN11 Q06124 1/20 0.44
KCNJ1 P48048 3/20 0.43
KCNH2 Q12809 2/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC1 Q13547 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30101497 1.00 RET (0.52) RETCYP3A4ALDH1A1HSD17B10HPGD
SCHEMBL16430486 0.92 RET (0.51) RETCYP3A4ALDH1A1HSD17B10HPGD
SCHEMBL21521519 0.92 RET (0.49) RETCYP3A4ALDH1A1HSD17B10HPGD
SCHEMBL21521793 0.92 RET (0.51) RETCYP3A4ALDH1A1HSD17B10HPGD
SCHEMBL16438702 0.87 USP2 (0.57) RETCYP3A4ALDH1A1HSD17B10HPGD
SCHEMBL21521374 0.87 HRH3 (0.48) RETCYP3A4ALDH1A1HSD17B10HPGD
SCHEMBL16432659 0.85 ALDH1A1 (0.50) RETCYP3A4ALDH1A1HSD17B10HPGD
SCHEMBL16430513 0.85 ALDH1A1 (0.56) RETCYP3A4ALDH1A1HSD17B10HPGD
SCHEMBL21521195 0.84 ALDH1A1 (0.46) RETALDH1A1HSD17B10HPGDCYP1A2
SCHEMBL16431326 0.79 KCNJ1 (0.46) KCNJ1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
EP-3788040-B1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-04-12 EP disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed
US-11014913-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
EP-3788040-A1 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2021-03-10 EP disclosed
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2021-01-28 US disclosed
US-10870641-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2020-12-22 US disclosed
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2020-04-23 US disclosed
US-10550105-B2 Pyridazinones as PARP7 inhibitors Ribon Therapeutics Inc. (US) 2020-02-04 US disclosed
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 RET 2740/4885CYP3A4 764/4885ALDH1A1 1033/4885
US-10550105-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 RET 2740/4885CYP3A4 764/4885ALDH1A1 1033/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 RET 2740/4885CYP3A4 764/4885ALDH1A1 1033/4885
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 RET 2740/4885CYP3A4 764/4885ALDH1A1 1033/4885
US-11014913-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 RET 2740/4885CYP3A4 764/4885ALDH1A1 1033/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 RET 2740/4885CYP3A4 764/4885ALDH1A1 1033/4885
US-10870641-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 RET 2740/4885CYP3A4 764/4885ALDH1A1 1033/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 RET 2740/4885CYP3A4 764/4885ALDH1A1 1033/4885
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 RET 2740/4885CYP3A4 764/4885ALDH1A1 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.